CN105232352A - Polypeptide compound for removing wrinkles in eyes and preparation method of polypeptide compound - Google Patents
Polypeptide compound for removing wrinkles in eyes and preparation method of polypeptide compound Download PDFInfo
- Publication number
- CN105232352A CN105232352A CN201510733991.9A CN201510733991A CN105232352A CN 105232352 A CN105232352 A CN 105232352A CN 201510733991 A CN201510733991 A CN 201510733991A CN 105232352 A CN105232352 A CN 105232352A
- Authority
- CN
- China
- Prior art keywords
- phase
- eyes
- acetyl
- tetrapeptide
- palmitoyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000037303 wrinkles Effects 0.000 title claims abstract description 34
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 15
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 15
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 150000001875 compounds Chemical class 0.000 title abstract 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 19
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 13
- IHRKJQSLKLYWBQ-QKDODKLFSA-N (2s)-2-[[(2s)-1-[(2s)-5-amino-2-[[2-(hexadecanoylamino)acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O IHRKJQSLKLYWBQ-QKDODKLFSA-N 0.000 claims abstract description 12
- ROTFCACGLKOUGI-JYJNAYRXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-(3-acetamidopropanoylamino)-3-(1h-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1h-imidazol-5-yl)propanoic acid Chemical compound C([C@H](NC(=O)CCNC(=O)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 ROTFCACGLKOUGI-JYJNAYRXSA-N 0.000 claims abstract description 12
- 229940094946 palmitoyl tetrapeptide-7 Drugs 0.000 claims abstract description 12
- 229940015975 1,2-hexanediol Drugs 0.000 claims abstract description 4
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims abstract description 4
- 238000003756 stirring Methods 0.000 claims description 40
- 239000000203 mixture Substances 0.000 claims description 16
- 239000000047 product Substances 0.000 claims description 13
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 11
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 11
- 239000004475 Arginine Substances 0.000 claims description 8
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 238000005374 membrane filtration Methods 0.000 claims description 8
- 239000011259 mixed solution Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 11
- WSGCRSMLXFHGRM-DEVHWETNSA-N (2s)-2-[[(2s)-6-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-3-hydroxypropanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O WSGCRSMLXFHGRM-DEVHWETNSA-N 0.000 abstract 1
- AJLNZWYOJAWBCR-OOPVGHQCSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=C)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O AJLNZWYOJAWBCR-OOPVGHQCSA-N 0.000 abstract 1
- 229920002385 Sodium hyaluronate Polymers 0.000 abstract 1
- LZDNBBYBDGBADK-KBPBESRZSA-N Val-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)C(C)C)C(O)=O)=CNC2=C1 LZDNBBYBDGBADK-KBPBESRZSA-N 0.000 abstract 1
- 239000008213 purified water Substances 0.000 abstract 1
- 229940010747 sodium hyaluronate Drugs 0.000 abstract 1
- 206010040954 Skin wrinkling Diseases 0.000 description 31
- 230000000052 comparative effect Effects 0.000 description 13
- 230000007423 decrease Effects 0.000 description 12
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- 102000004183 Synaptosomal-Associated Protein 25 Human genes 0.000 description 2
- 108010057722 Synaptosomal-Associated Protein 25 Proteins 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000010612 desalination reaction Methods 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 230000037331 wrinkle reduction Effects 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000000715 neuromuscular junction Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 230000008326 skin blood flow Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention provides a polypeptide compound for removing wrinkles in eyes. The polypeptide compound, in percentage by mass, consists of the following components: 0.02-0.035% of acetyl hexapeptide-3, 0.001-0.01% of palmitoyl pentapeptide-3, 0.025-0.035% of palmitoyl tetrapeptide-7, 0.025-0.035% of tripeptide, 0.08-0.12% of dipeptide-2, 0.1-0.2% of acetyl tetrapeptide-5, 4-6% of glycerol, 0.2-0.4% of sodium hyaluronate, 0.3-0.5% of 1,2-hexanediol and the balance of purified water. Correspondingly, the invention also provides a preparation method of the compound. The polypeptide compound for removing wrinkles in eyes provided by the invention, applied to volunteers, is capable of taking a significant effect of relieving wrinkles in eyes, so that the average quantity of the wrinkles in eyes is reduced, the depth of the wrinkles in eyes is reduced, the smoothness of eye skin is enhanced, the coverage area of the wrinkles in eyes is reduced and the phenomenon of the wrinkles in eyes is significantly improved.
Description
Technical field
The present invention relates to a kind of polypeptide complex for eye wrinkle removing and preparation method thereof, this complex is mainly used in eye skin, has the effect of wrinkle reduction, slow down aging.
Background technology
Skin around the eyes is position the thinnest in all skin of human body, only has the thickness of skin of face 1/4th, does not almost have the distribution of sebaceous gland and sweat gland, thus natural moist ability is not had, moisture is preserved not easily, easily causes dry hydropenia, causes skin around the eyes very easily old and feeble.With advancing age, easily there is wrinkle, expression stricture of vagina, crows-feet in eye skin, follows the string and consolidation, lax sagging.
Anti-wrinkle product conventional is at present various, and effect is variant greatly, and most of product usually cannot improve skin metabolism, promotes cutaneous circulation, increase skin-nourishing, fundamentally cannot remove wrinkle and the mottle of skin appearance.And most product is containing heavy metal, the still difficult prediction of safety and sequela, if improper use, may after cause the damage of skin.
Summary of the invention
For above-mentioned technical problem, the invention provides a kind of polypeptide complex for eye wrinkle removing, adopt micromolecule polypeptide, molecular weight is little, do not need the auxiliary deep layer that just can directly independently penetrate to the skin of other permeation-promoter, dredging blood capillary, reduce blood viscosity, accelerate blood flow rate, improve facial microcirculation, cuticle thickness is reduced after facilitating skin of face metabolism, cell is made to obtain sufficient nutrient, improve the self-repairing capability of cell, fundamentally improve skin, dispel, desalination eye wrinkle-removing, accordingly, present invention also offers the preparation method of this complex.
In order to realize technical purpose of the present invention, the present invention by the following technical solutions.
A kind of polypeptide complex for eye wrinkle removing, by mass percentage, composed of the following components: the Palmitoyl Tetrapeptide-7 of acetyl six peptide-3 of 0.02%-0.035%, the Matrixyl-3 of 0.001%-0.01%, 0.025%-0.035%, the palmitoyl tripeptide 3 of 0.025%-0.035%, the dipeptides-2 of 0.08%-0.12%, the acetyl tetrapeptide-5 of 0.1%-0.2%, the glycerol of 4%-6%, the hyaluronate sodium of 0.2%-0.4%, 1 of 0.3%-0.5%, 2-hexanediol, surplus is pure water.
Accordingly, present invention also offers the preparation method of this complex, comprise the steps:
A () adds the pure water of 70%-80% by proportioning, heating, adds 1,2-hexanediol, stirs after making it dissolve, is divided into two parts, is respectively A phase, B phase;
B () keeps A phase temperature to be 50 DEG C-80 DEG C, stir and add hyaluronate sodium, continues stirring and makes it dissolve mix homogeneously, then add glycerol, continue to be uniformly mixed, as I phase;
C acetyl six peptide-3, Matrixyl-3, Palmitoyl Tetrapeptide-7, palmitoyl tripeptide 3, acetyl tetrapeptide-5, dipeptides-2 join in B phase by (), after stirring and dissolving mix homogeneously, with membrane filtration, gained filtrate is II phase;
D () is added to II in I phase under stirring, rinse the container of II phase respectively, and joined in I phase by rinse liquid, be uniformly mixed with the pure water of residue proportional quantity;
E () regulates mixed solution pH value to be 6.0-7.0 with arginine, gained complex is product of the present invention.
Preferably, in described step (a), heating-up temperature is 80 DEG C.
Preferably, in described step (c), the worry hole of filter membrane is 0.45 μm.
Preferably, in described step (e), arginic concentration is 15wt%.
A kind of polypeptide complex for eye wrinkle removal provided by the invention, according to feature and the wrinkle Forming Mechanism of eye skin, suppress Angiotensin-Converting active by adding acetyl tetrapeptide-5, lax blood capillary tension force is to promote blood flow, accelerate eye skin blood circulation, there is edema function; Add dipeptides-2, can blood circulation be strengthened, accelerate blood flow rate, promote new city metabolism; Add acetyl six peptide-3, imitate SNAP-25 protein N terminal, the SNAP-25 that participates in the competition is in the site of melting bubble complex, thus the configuration of REGULATOR, and it is slightly unstable to melt bubble complex, and vesicle can not effective release neurotransmitters, cause muscle contraction to weaken, prevent the formation of wrinkle; Add palmitoyl tripeptide 3 reduce wrinkle, can suppress the release of neuromuscular junction acetylcholine, muscle tone is declined or paralysis, wrinkle also fades away thereupon, thus reaches the object of wrinkle reduction; Add Matrixyl-3 and promote that collagen protein generates, prevent because collagen protein reduces and generate wrinkle; And add the effect that Palmitoyl Tetrapeptide-7 has reduction inflammation; Hyaluronate sodium and glycerol are a kind of wetting agents; 1,2-hexanediol has the effect of anti-bacteria wet keeping, improves the holding time of blending ingredients.
The beneficial effect that the present invention has is:
(1) micromolecule polypeptide added can independently directly penetrate to the skin skin corium, easily be absorbed by the skin, the skin freely do not caused due to blood can be solved and cross the problems such as the eye wrinkle-removing that presenility causes, the effect of wrinkle removing stricture of vagina is very good, face blood microcirculation can be improved simultaneously, promote that skin collagen generates, there is the effect improving skin quality.
(2) add hyaluronate sodium and glycerol as skin-moisturizing, skin antioxidative raw material, have and crease-resistantly preferably go microgroove effect.
(3) technological process of production is simple.
Detailed description of the invention
For a better understanding of the present invention, be described in detail invention below in conjunction with embodiment, if no special instructions, following examples all by percentage to the quality.
Embodiment 1:
A () adds the pure water of 70% by proportioning, be heated to 80 DEG C, adds 1, the 2-hexanediol of 0.3%, stirs after making it dissolve, is divided into two parts, is respectively A phase, B phase;
B () keeps A phase temperature to be 50 DEG C, stir the hyaluronate sodium adding 0.4%, continues stirring and makes it dissolve mix homogeneously, then add the glycerol of 4%, continue to be uniformly mixed, as I phase;
(c) by acetyl six peptide-3 of 0.02%, 0.01% Matrixyl-3,0.025% Palmitoyl Tetrapeptide-7, the palmitoyl tripeptide 3 of 0.035%, the acetyl tetrapeptide-5 of 0.1% and 0.08% dipeptides-2 join in B phase, after stirring and dissolving mix homogeneously, with the membrane filtration that worry hole is 0.45 μm, gained filtrate is II phase;
D () is added to II in I phase under stirring, rinse the container of II phase respectively, and joined in I phase by rinse liquid, be uniformly mixed with the pure water of residue proportional quantity;
E () regulates mixed solution pH value to be 6.0-7.0 with the arginine of 15wt%, gained complex is the embodiment of the present invention 1 product.
Embodiment 2:
A () adds the pure water of 80% by proportioning, be heated to 80 DEG C, adds 1, the 2-hexanediol of 0.5%, stirs after making it dissolve, is divided into two parts, is respectively A phase, B phase;
B () keeps A phase temperature to be 60 DEG C, stir the hyaluronate sodium adding 0.4%, continues stirring and makes it dissolve mix homogeneously, then add the glycerol of 5%, continue to be uniformly mixed, as I phase;
(c) by acetyl six peptide-3 of 0.025%, 0.007% Matrixyl-3,0.035% Palmitoyl Tetrapeptide-7, the palmitoyl tripeptide 3 of 0.035%, the acetyl tetrapeptide-5 of 0.1% and 0.1% dipeptides-2 join in B phase, after stirring and dissolving mix homogeneously, with the membrane filtration that worry hole is 0.45 μm, gained filtrate is II phase;
D () is added to II in I phase under stirring, rinse the container of II phase respectively, and joined in I phase by rinse liquid, be uniformly mixed with the pure water of residue proportional quantity;
E () regulates mixed solution pH value to be 6.0-7.0 with the arginine of 15wt%, gained complex is the embodiment of the present invention 2 product.
Embodiment 3:
A () adds the pure water of 80% by proportioning, be heated to 80 DEG C, adds 1, the 2-hexanediol of 0.4%, stirs after making it dissolve, is divided into two parts, is respectively A phase, B phase;
B () keeps A phase temperature to be 70 DEG C, stir the hyaluronate sodium adding 0.2%, continues stirring and makes it dissolve mix homogeneously, then add the glycerol of 6%, continue to be uniformly mixed, as I phase;
(c) by acetyl six peptide-3 of 0.03%, 0.001% Matrixyl-3,0.03% Palmitoyl Tetrapeptide-7, the palmitoyl tripeptide 3 of 0.03%, the acetyl tetrapeptide-5 of 0.15% and 0.12% dipeptides-2 join in B phase, after stirring and dissolving mix homogeneously, with the membrane filtration that worry hole is 0.45 μm, gained filtrate is II phase;
D () is added to II in I phase under stirring, rinse the container of II phase respectively, and joined in I phase by rinse liquid, be uniformly mixed with the pure water of residue proportional quantity;
E () regulates mixed solution pH value to be 6.0-7.0 with the arginine of 15wt%, gained complex is the embodiment of the present invention 3 product.
Embodiment 4:
A () adds the pure water of 75% by proportioning, be heated to 80 DEG C, adds 1, the 2-hexanediol of 0.5%, stirs after making it dissolve, is divided into two parts, is respectively A phase, B phase;
B () keeps A phase temperature to be 80 DEG C, stir the hyaluronate sodium adding 0.3%, continues stirring and makes it dissolve mix homogeneously, then add the glycerol of 6%, continue to be uniformly mixed, as I phase;
(c) by acetyl six peptide-3 of 0.035%, 0.005% Matrixyl-3,0.032% Palmitoyl Tetrapeptide-7, the palmitoyl tripeptide 3 of 0.025%, the acetyl tetrapeptide-5 of 0.2% and 0.12% dipeptides-2 join in B phase, after stirring and dissolving mix homogeneously, with the membrane filtration that worry hole is 0.45 μm, gained filtrate is II phase;
D () is added to II in I phase under stirring, rinse the container of II phase respectively, and joined in I phase by rinse liquid, be uniformly mixed with the pure water of residue proportional quantity;
E () regulates mixed solution pH value to be 6.0-7.0 with the arginine of 15wt%, gained complex is the embodiment of the present invention 4 product.
Comparative example 5 (not containing acetyl six peptide-3):
A () adds the pure water of 75% by proportioning, be heated to 80 DEG C, adds 1, the 2-hexanediol of 0.5%, stirs after making it dissolve, is divided into two parts, is respectively A phase, B phase;
B () keeps A phase temperature to be 80 DEG C, stir the hyaluronate sodium adding 0.3%, continues stirring and makes it dissolve mix homogeneously, then add the glycerol of 6%, continue to be uniformly mixed, as I phase;
The Matrixyl-3 of (c) 0.005%, the Palmitoyl Tetrapeptide-7 of 0.032%, the palmitoyl tripeptide 3 of 0.025%, the acetyl tetrapeptide-5 of 0.2% and 0.12% dipeptides-2 join in B phase, after stirring and dissolving mix homogeneously, with the membrane filtration that worry hole is 0.45 μm, gained filtrate is II phase;
D () is added to II in I phase under stirring, rinse the container of II phase respectively, and joined in I phase by rinse liquid, be uniformly mixed with the pure water of residue proportional quantity;
E () regulates mixed solution pH value to be 6.0-7.0 with the arginine of 15wt%, gained complex is comparative example 5 product of the present invention.
Comparative example 6 (not containing acetyl tetrapeptide-5):
A () adds the pure water of 80% by proportioning, be heated to 80 DEG C, adds 1, the 2-hexanediol of 0.4%, stirs after making it dissolve, is divided into two parts, is respectively A phase, B phase;
B () keeps A phase temperature to be 70 DEG C, stir the hyaluronate sodium adding 0.2%, continues stirring and makes it dissolve mix homogeneously, then add the glycerol of 6%, continue to be uniformly mixed, as I phase;
(c) by acetyl six peptide-3 of 0.03%, 0.001% Matrixyl-3, the Palmitoyl Tetrapeptide-7 of 0.03%, the palmitoyl tripeptide 3 of 0.03% and 0.12% dipeptides-2 join in B phase, after stirring and dissolving mix homogeneously, with the membrane filtration that worry hole is 0.45 μm, gained filtrate is II phase;
D () is added to II in I phase under stirring, rinse the container of II phase respectively, and joined in I phase by rinse liquid, be uniformly mixed with the pure water of residue proportional quantity;
E () regulates mixed solution pH value to be 6.0-7.0 with the arginine of 15wt%, gained complex is comparative example 6 product of the present invention.
Select wrinkle obvious healthy volunteer 180, the mean age is 50.4 years old, is divided into 6 groups, tests respectively to the product of embodiment 1-4 products obtained therefrom and comparative example 5, comparative example 6.Every day smears described complex in circumference of eyes sooner or later, and anti-aging effects detects by profile and graphical analysis, takes pictures and compares.
Before and after embodiment 1-4 and comparative example 5,6 use, 28 days, 56 days results of use are respectively as shown in table 1, table 2.
Table 1 embodiment and comparative example use the eye wrinkle removal effect after 28 days
| Test item | Embodiment 1 | Embodiment 2 | Embodiment 3 | Embodiment 4 | Comparative example 5 | Comparative example 6 |
| Wrinkle number | Reduce 28.7% | Reduce 29.1% | Reduce 27.4% | Reduce 25.2% | Reduce 19.9% | Reduce 22.7% |
| Wrinkle depth | Shoal 19.8% | Shoal 21.7% | Shoal 18.2% | Shoal 16.4% | Shoal 13.7% | Shoal 15.2% |
| Eye part skin smoothness | Improve 30.8% | Improve 32.7% | Improve 31.2% | Improve 29.4% | Improve 20.9% | Improve 24.5% |
| Wrinkle area coverage | Decline 33.4% | Decline 34.5% | Decline 30.7% | Decline 32.2% | Decline 21.7% | Decline 25.6% |
Table 2 embodiment and comparative example use the eye wrinkle removal effect after 56 days
| Test item | Embodiment 1 | Embodiment 2 | Embodiment 3 | Embodiment 4 | Comparative example 5 | Comparative example 6 |
| Wrinkle number | Reduce 35.7% | Reduce 36.4% | Reduce 35.0% | Reduce 35.9% | Reduce 24.9% | Reduce 28.0% |
| Wrinkle depth | Shoal 26.4% | Shoal 27.8% | Shoal 25.9% | Shoal 26.3% | Shoal 20.8% | Shoal 22.4% |
| Eye part skin smoothness | Improve 43.2% | Improve 41.6% | Improve 41.2% | Improve 42.1% | Improve 24.7% | Improve 27.9% |
| Wrinkle area coverage | Decline 43.9% | Decline 44.3% | Decline 43.2% | Decline 42.7% | Decline 29.6% | Decline 31.1% |
Can obviously find out according to upper table data, after using a kind of polypeptide complex for eye wrinkle removal provided by the invention, volunteer all has the effect of significantly desalination eye wrinkle-removing, the decreased number of the average wrinkle of eye, eye wrinkle-removing depth shallower, the smoothness of eye part skin improves, and the area coverage of eye wrinkle-removing declines, and eye wrinkle-removing phenomenon has clear improvement.
More than show and describe ultimate principle of the present invention, principal character and advantage.The technical staff of the industry should understand, and above-described embodiment does not limit the present invention in any form, the technical scheme that the mode that all employings are equal to replacement or equivalent transformation obtains, and all drops in protection scope of the present invention.
Claims (5)
1. the polypeptide complex for eye wrinkle removing, it is characterized in that, by mass percentage, composed of the following components: the Palmitoyl Tetrapeptide-7 of acetyl six peptide-3 of 0.02%-0.035%, the Matrixyl-3 of 0.001%-0.01%, 0.025%-0.035%, the palmitoyl tripeptide 3 of 0.025%-0.035%, the dipeptides-2 of 0.08%-0.12%, the acetyl tetrapeptide-5 of 0.1%-0.2%, the glycerol of 4%-6%, the hyaluronate sodium of 0.2%-0.4%, 1 of 0.3%-0.5%, 2-hexanediol, surplus is pure water.
2. the preparation method of a kind of polypeptide complex for eye wrinkle removing according to claim 1, is characterized in that, comprise the following steps:
A () adds the pure water of 70%-80% by proportioning, heating, adds 1,2-hexanediol, stirs after making it dissolve, is divided into two parts, is respectively A phase, B phase;
B () keeps A phase temperature to be 50 DEG C-80 DEG C, stir and add hyaluronate sodium, continues stirring and makes it dissolve mix homogeneously, then add glycerol, continue to be uniformly mixed, as I phase;
C acetyl six peptide-3, Matrixyl-3, Palmitoyl Tetrapeptide-7, palmitoyl tripeptide 3, acetyl tetrapeptide-5, dipeptides-2 join in B phase by (), after stirring and dissolving mix homogeneously, with membrane filtration, gained filtrate is II phase;
D () is added to II in I phase under stirring, rinse the container of II phase respectively, and joined in I phase by rinse liquid, be uniformly mixed with the pure water of residue proportional quantity;
E () regulates mixed solution pH value to be 6.0-7.0 with arginine, gained complex is product of the present invention.
3. method according to claim 2, is characterized in that: in described step (a), heating-up temperature is 80 DEG C.
4. method according to claim 2, is characterized in that: in described step (c), the filter opening of filter membrane is 0.45 μm.
5. method according to claim 2, is characterized in that: in described step (e), arginic concentration is 15wt%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510733991.9A CN105232352B (en) | 2015-10-30 | 2015-10-30 | A kind of polypeptide complex that wrinkle is gone for eye and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510733991.9A CN105232352B (en) | 2015-10-30 | 2015-10-30 | A kind of polypeptide complex that wrinkle is gone for eye and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105232352A true CN105232352A (en) | 2016-01-13 |
| CN105232352B CN105232352B (en) | 2018-02-09 |
Family
ID=55030364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510733991.9A Active CN105232352B (en) | 2015-10-30 | 2015-10-30 | A kind of polypeptide complex that wrinkle is gone for eye and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105232352B (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106344426A (en) * | 2016-10-08 | 2017-01-25 | 广州丹奇日用化工厂有限公司 | Retina containing new zealand spinach polypeptide |
| CN106726668A (en) * | 2016-11-19 | 2017-05-31 | 诺斯贝尔化妆品股份有限公司 | A kind of many peptidoliposome raw materials used in cosmetics |
| CN107308020A (en) * | 2017-07-06 | 2017-11-03 | 珠海联邦制药股份有限公司 | A kind of peptide composition of stabilization and its application |
| CN107550755A (en) * | 2017-10-27 | 2018-01-09 | 广州市花安堂生物科技有限公司 | A kind of composition of gentle moisturizing desalination microgroove and preparation method thereof |
| CN108078801A (en) * | 2017-12-22 | 2018-05-29 | 安婕妤化妆品科技股份有限公司 | A kind of eye cosmetic composition |
| CN108338934A (en) * | 2017-01-23 | 2018-07-31 | 珠海联邦制药股份有限公司 | A kind of peptide composition and its application for eye-care |
| CN109745280A (en) * | 2017-11-01 | 2019-05-14 | 郑州艾之宝科技有限公司 | The net face epithelium of Chinese medicine |
| CN113116742A (en) * | 2021-04-29 | 2021-07-16 | 山东优杰生物科技有限公司 | Composite polypeptide anti-wrinkle composition and preparation method and application thereof |
| CN114073662A (en) * | 2020-08-11 | 2022-02-22 | 广东长昊药业股份有限公司 | Intelligent care mother solution for eye and preparation method thereof |
| CN115624504A (en) * | 2022-03-08 | 2023-01-20 | 广州市万千粉丝化妆品有限公司 | Application of small molecular tissue active peptide in anti-wrinkle and anti-aging cosmetics for promoting skin collagen reconstruction and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040180026A1 (en) * | 2004-03-10 | 2004-09-16 | Tammy Ha | Topical skin care composition |
| WO2008151890A1 (en) * | 2007-06-11 | 2008-12-18 | Chanel Parfums Beaute | Use of active agents for stimulating the expression of fn3k and/or fn3k rp for combating ageing of the skin |
| CN103494715A (en) * | 2013-07-17 | 2014-01-08 | 吴克 | Eye anti-wrinkle essence |
| CN104622779A (en) * | 2015-01-08 | 2015-05-20 | 上海圣婕化妆品有限公司 | Antiageing and repairing polypeptide facial mask essence and preparation method thereof |
| CN104739723A (en) * | 2015-03-19 | 2015-07-01 | 广东轻工职业技术学院 | Tightening eye cream |
-
2015
- 2015-10-30 CN CN201510733991.9A patent/CN105232352B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040180026A1 (en) * | 2004-03-10 | 2004-09-16 | Tammy Ha | Topical skin care composition |
| WO2008151890A1 (en) * | 2007-06-11 | 2008-12-18 | Chanel Parfums Beaute | Use of active agents for stimulating the expression of fn3k and/or fn3k rp for combating ageing of the skin |
| CN103494715A (en) * | 2013-07-17 | 2014-01-08 | 吴克 | Eye anti-wrinkle essence |
| CN104622779A (en) * | 2015-01-08 | 2015-05-20 | 上海圣婕化妆品有限公司 | Antiageing and repairing polypeptide facial mask essence and preparation method thereof |
| CN104739723A (en) * | 2015-03-19 | 2015-07-01 | 广东轻工职业技术学院 | Tightening eye cream |
Non-Patent Citations (1)
| Title |
|---|
| 陈洁: "《别再错误护肤啦！》", 31 July 2010, 北方妇女儿童出版社 * |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106344426A (en) * | 2016-10-08 | 2017-01-25 | 广州丹奇日用化工厂有限公司 | Retina containing new zealand spinach polypeptide |
| CN106726668A (en) * | 2016-11-19 | 2017-05-31 | 诺斯贝尔化妆品股份有限公司 | A kind of many peptidoliposome raw materials used in cosmetics |
| CN108338934A (en) * | 2017-01-23 | 2018-07-31 | 珠海联邦制药股份有限公司 | A kind of peptide composition and its application for eye-care |
| CN107308020A (en) * | 2017-07-06 | 2017-11-03 | 珠海联邦制药股份有限公司 | A kind of peptide composition of stabilization and its application |
| CN107550755A (en) * | 2017-10-27 | 2018-01-09 | 广州市花安堂生物科技有限公司 | A kind of composition of gentle moisturizing desalination microgroove and preparation method thereof |
| CN107550755B (en) * | 2017-10-27 | 2019-01-25 | 花安堂生物科技集团有限公司 | A kind of composition and preparation method thereof of mild moisturizing desalination microgroove |
| CN109745280A (en) * | 2017-11-01 | 2019-05-14 | 郑州艾之宝科技有限公司 | The net face epithelium of Chinese medicine |
| CN108078801A (en) * | 2017-12-22 | 2018-05-29 | 安婕妤化妆品科技股份有限公司 | A kind of eye cosmetic composition |
| CN114073662A (en) * | 2020-08-11 | 2022-02-22 | 广东长昊药业股份有限公司 | Intelligent care mother solution for eye and preparation method thereof |
| CN113116742A (en) * | 2021-04-29 | 2021-07-16 | 山东优杰生物科技有限公司 | Composite polypeptide anti-wrinkle composition and preparation method and application thereof |
| CN115624504A (en) * | 2022-03-08 | 2023-01-20 | 广州市万千粉丝化妆品有限公司 | Application of small molecular tissue active peptide in anti-wrinkle and anti-aging cosmetics for promoting skin collagen reconstruction and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105232352B (en) | 2018-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105232352A (en) | Polypeptide compound for removing wrinkles in eyes and preparation method of polypeptide compound | |
| CN111166690A (en) | Skin anti-aging oligopeptide composition and preparation method thereof | |
| CN105272968B (en) | The diketone of (3S, 6R) 3,6 disubstituted piperazine 2,5, it is prepared and application | |
| CN111870540A (en) | Medical repairing facial mask and preparation method thereof | |
| CN104327747B (en) | A kind of enzyme process prepares the production method of pharmagel | |
| CN107753389A (en) | A kind of recombined collagen foaming pectin facial mask and preparation method thereof | |
| CN115990127B (en) | Composition with pore shrinking and skin smoothing functions, and preparation method and application thereof | |
| CN112587434B (en) | Hair blackening agent, preparation method of hair blackening agent and washing and caring liquid | |
| CN104812374A (en) | Silk hydrogel composition and silk hydrogel mask | |
| CN105362089B (en) | A kind of whitening emollient cream and preparation method thereof | |
| CN107669525A (en) | Application of Poria cocos extract solution with brilliant white effect and preparation method thereof | |
| CN104153185B (en) | Chloroperoxidase catalysis oxidation hair decolorising agent and the method decolourized and application | |
| CN104371559B (en) | A kind of production technology of pharmagel | |
| CN106821901A (en) | A kind of creme with the wrinkle of skin effect of reduction circumference of eyes | |
| CN107349162A (en) | A kind of cleawhite pack prepared using banana skin and preparation method thereof | |
| CN109528534A (en) | A kind of tender face water of moisturizing and preparation method thereof | |
| JP3559383B2 (en) | Production method of liquefied brewed sake | |
| CN108324589A (en) | A kind of composition for whitening skin and preparation method thereof | |
| CN107714614A (en) | A kind of preparation method of anti-wrinkle eye cream | |
| CN107603276A (en) | A kind of biological stain of stabilization and preparation method thereof | |
| CN113332208B (en) | Anti-inflammatory repair emulsion containing corn germ extracting solution | |
| CN110893154A (en) | Skin care product for removing oil on face and preparation process thereof | |
| KR102665183B1 (en) | Method for preparing a eutectic solvent containing vitamin C and enzymatically treated betaine | |
| CN109528586A (en) | One kind is based on private gene customization spot-eliminating composition and preparation method thereof | |
| CN107217515A (en) | A kind of colouring method of terylene fleece |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220425 Address after: 528400 second floor, plant 1, No. 13, Maonan Road, South China Modern Traditional Chinese medicine city, Nanlang street, Zhongshan City, Guangdong Province Patentee after: Kasi biological (Guangdong) Technology Co.,Ltd. Address before: 528400 4th floor, No.2 factory building, South China Modern Chinese medicine city science park, Nanlang Town, Zhongshan City, Guangdong Province Patentee before: ZHONGSHAN CASSIEY BIOTECHNOLOGY Co.,Ltd. |